Table 2.
PK parameters of NIC after a single oral administration of Yomesan®, NIC–DHT/Tween 60 and NIC–DHT/HPMC nanohybrid formulations in rats (** only the Yomesan® data shown here were reused from Reference [51] (This data shown here is reused under Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/), which was our previous study related to NIC-MMT nanohybrids) (n = 5).
| Parameters | ** Yomesan®
(50 mg/kg) |
NIC–DHT/Tween 60 (50 mg/kg) |
NIC–DHT/Tween 60 (200 mg/kg) | NIC–DHT/HPMC (200 mg/kg) |
|---|---|---|---|---|
| AUC(last)
(ng·h/mL) |
1096.81 ± 359.28 | 1823.83 ± 305.26 | 6819.30 ± 2530.40 | 30,430.35 ± 10,921.98 |
| Cmax (ng /mL) | 155.27 ± 39.92 | 1350.37 ± 613.98 | 6316.60 ± 4270.00 | 18,928.63 ± 2934.34 |
| Tmax (h) | 4.00 ± 0.89 | 0.25 ± 0.00 | 0.25 ± 1.65 | 0.38 ± 0.14 |
| T1/2 (h) | 5.72 ± 6.09 | 3.19 ± 0.43 | 2.69 ± 1.46 | 6.75 ± 1.98 |
AUC = area under the plasma concentration–time curve; Cmax = maximum plasma concentration; Tmax = time required to reach Cmax; t1/2 = elimination half-life.